-in
-class SK2 selective inhibitor targeting multiple indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; (iii)
RHB-107 (
upamostat), a serine protease inhibitor in a U.S. Phase 2/3 study as treatment for symptomatic COVID-19, and targeting multiple other cancer and inflammatory gastrointestinal diseases; (iv)
RHB-104, with positive results from a first Phase 3 study for Crohn s disease; (v)
RHB-102 (
Bekinda
®), with positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; and (vi)
RHB-
106, an encapsulated bowel preparation. More information about the Company is available at www.redhillbio.com / https://twitter.com/RedHillBio.
/PRNewswire/ AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that due to demand, the underwriter has agreed to increase the.
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results Supplemental NDA accepted by FDA for AYVAKIT™ (avapritinib) for advanced systemic mastocytosis Type II variation MAA submitted to EMA for AYVAKYT® (avapritinib) for advanced systemic mastocytosis Announced a potential best-in-class research program targeting CDK2 for the treatment of multiple cancers with tumor-associated cell cycle defects Plan to provide updates across multiple clinical and research programs at AACR 2021 Annual Meeting Ended 2020 with approximately $1.5 billion in cash
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., Feb. 17, 2021 /PRNewswire/ Blueprint Medicines Corporation (NASDAQ:BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2020.
increases Canada s testing capacity at the point of care.
Antigen test reliably and quickly triages people suspected of COVID-19 , with results ready in 15 minutes, allowing informed decisions including rapid isolation
The test has a sensitivity of 86.2%-90.0% and a specificity of 97.9%-99.3%, based on 1,106 samples collected from patients from two independent study centers
1
The instrument-free testing kit enables convenient use and a seamless workflow for healthcare professionals at different point of care locations or in resource-limited settings
LAVAL, QC, Feb. 17, 2021 /CNW Telbec/ - Subsequent to its global distribution agreement with SD Biosensor Inc.,
Roche Diagnostics, a division of Hoffmann-La Roche Limited, announces that its SARS-CoV-2 Rapid Antigen Test has received approval under Health Canada s Interim Order. This can help healthcare professionals identify a SARS-CoV-2 infection with results typically ready in 15 minutes.
Share this article
Share this article
PROVIDENCE, R.I., Feb. 17, 2021 /PRNewswire/ EpiVax, Inc. ( EpiVax ) today announces its participation in the INDIGO consortium – a partnership of public and private research and development organizations from the EU, India, and United States (funded by the EU and India) with the aim of developing next-generation influenza vaccines with better responsiveness, lower costs, and better accessibility.
The INDIGO consortium, led by Dr. Remko van Leeuwen (INDIGO s Principal Investigator) of the Amsterdam Institute for Global Health and Development ( AIGHD ), plans to achieve this goal by exploring innovative influenza vaccine concepts. The group will aim to produce novel seasonal (A and B) and avian flu (H7N9 and H5N1) vaccines by combining three cutting-edge elements: novel recombinant HAs with increased immunogenicity, a potent adjuvant, and delivery via needle-free intradermal patches. The consortium will seek to validate this approach by sh